Latest News

PerimeterX Delivers Web Application Security through Google Cloud Platform Marketplace

PerimeterX, the leading provider of application security solutions that keep web businesses safe in the digital world, today announced the availability of PerimeterX Bot Defender on Google Cloud Platform Marketplace (GCP Marketplace), providing customers with the ability to protect web and mobile applications and APIs from automated attacks and to safeguard their consumers’ digital experience.

27 Nov 2019
Read more

Cymulate raises $15 million to expand its cloud-based security platform

Cymulate today announced that it has raised $15 million in venture capital as the cybersecurity company continues international expansion of its cloud-based platform.

27 Nov 2019
Read more

PerimeterX Named Overall CyberSecurity Startup of the Year in 2019 CyberSecurity Breakthrough Awards Program

PerimeterX, the leading provider of application security solutions that keep web businesses safe in the complex digital world, today announced that it has been named the winner of the “Overall CyberSecurity Startup of the Year” award in the 2019 CyberSecurity Breakthrough Awards program from CyberSecurity Breakthrough, a leading independent market intelligence organization that recognizes the top companies, technologies and products in the global information security market today.

02 Oct 2019
Read more

Singapore's Vertex adds $290 million venture fund for high-growth tech firms

Vertex Growth Fund achieves a resounding final close of its inaugural fund – Vertex Growth Fund I – at USD290 million. Demand for the fund surpassed the initial target fund size of USD250 million.

12 Sep 2019
Read more

Bicycle Therapeutics & Oxurion: Positive Topline Phase 1 Results with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME)

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, today reports positive topline data from a Phase 1 study with THR-149, a novel, potent, plasma kallikrein (PKal) inhibitor for the treatment of Diabetic Macular Edema (DME).

01 Jul 2019
Read more

Nuvaira: Revolutionary therapy that blasts 80°C radiofrequency into defective lung nerves could help thousands of sufferers with severe asthma

Nuvaira deploys a ground-breaking therapy called targeted lung denervation. It’s based on the discovery that a faulty nerve that runs from the brain to the lungs may be partly to blame for asthma flare-ups.

06 Jun 2019
Read more